Evidence map›Paper›PMID 28031722›Full record

ArticleOncoTargets and therapy2017

Low

Ya Cheng, Song-Ge Xing, Wei-Dong Jia, Mei Huang, Na-Na Bian

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Identification ofFrontiers in genetics · 2022
    Article
  4. Article
  5. Frontiers in genetics · 2021
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ya ChengDepartment of General Surgery, Affiliated Provincial Hospital, Anhui Medical University; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery.
Song-Ge XingAnhui Province Key Laboratory of Hepatopancreatobiliary Surgery; CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Science, University of Science and Technology of China, Hefei, People's Republic of China.
Wei-Dong JiaDepartment of General Surgery, Affiliated Provincial Hospital, Anhui Medical University; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery.
Mei HuangDepartment of General Surgery, Affiliated Provincial Hospital, Anhui Medical University; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery.
Na-Na BianAnhui Province Key Laboratory of Hepatopancreatobiliary Surgery.
Anhui Provincial Hospital · CNUniversity of Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious reports show that phospholipase C epsilon-1 ( MATERIALS AND

methods

resultsWe found that the expression of

conclusionIn brief, our results revealed that decreased

Indexed as

hepatocellular carcinomaimmunohistochemistryPLCE1prognosis

Identifiers

PMID28031722
PMCPMC5182043
OpenAlexW2564519035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.